NCT03670043 is a Phase 4 clinical trial of Psyllium powder in Type2 Diabetes Mellitus, sponsored by West Side Institute for Science and Education.

Who is sponsoring NCT03670043?

NCT03670043 is sponsored by West Side Institute for Science and Education.

What drugs are being tested in NCT03670043?

Interventions in NCT03670043: Psyllium powder, Metformin Extended Release Oral Tablet.

What condition does NCT03670043 study?

NCT03670043 studies Type2 Diabetes Mellitus.

Is NCT03670043 still recruiting?

NCT03670043 is currently completed. Last updated 10 September 2021.

Last reviewed 2021-09-10 · How we verify

NCT03670043

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tolerance & Responsiveness Improvement for Metformin (TRIM)

Completed Phase 4 Last updated 10 September 2021

What this trial tests

Phase 4 trial testing Psyllium powder in Type2 Diabetes Mellitus in 29 participants. Completed in 15 August 2021.

Timeline

19 March 2019

Primary endpoint
15 October 2020

15 August 2021

Quick facts

Lead sponsor	West Side Institute for Science and Education
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	29
Start date	19 March 2019
Primary completion	15 October 2020
Estimated completion	15 August 2021
Sites	1 location across United States

Drugs / interventions tested

Psyllium powder — full drug profile →
Metformin Extended Release Oral Tablet

Conditions studied

Type2 Diabetes Mellitus — all drugs for Type2 Diabetes Mellitus →

Sponsor

West Side Institute for Science and Education

Who can join

Adults 20 to 70, male only, with Type2 Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The overall goal is to explore the hypothesis that prebiotic fiber Psyllium will ameliorate diarrhea in African American men (AAM) with Type2 Diabetes Mellitus (T2D).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Type2 Diabetes Mellitus

Currently open trials in the same condition.

NCT07533604 — SnapDandCGMinType2Diabetes · NA · recruiting
NCT06961019 — Clinical Study to Assess the Safety, Efficacy and In-Use Tolerability of Herbal-Based Sugar Support Effervescent Tablets · NA · recruiting
NCT06497842 — Effort During Resistance Training in Type 2 Diabetes · NA · active not recruiting
NCT06257966 — A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type · Phase 3 · active not recruiting
NCT03647306 — Behavioral Chronotype: Impact on Sleep and Metabolism · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03670043 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by West Side Institute for Science and Education
Last refreshed: 10 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03670043.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing